Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2016

Publisher Name :
Date: 26-Oct-2016
No. of pages: 52

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2016', provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

  • The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Overview 7
Therapeutics Development 8
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Stage of Development 8
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Therapy Area 9
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Indication 10
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Companies 13
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Universities/Institutes 15
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development 24
Bayer AG 24
Bristol-Myers Squibb Company 25
Ionis Pharmaceuticals, Inc. 26
LegoChem Biosciences, Inc 27
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles 28
AB-012 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
AB-022 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BAY-1213790 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BMS-262084 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
BMS-654457 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
coagulation factor XI (human) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
coagulation factor XI (human) - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
EP-7041 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
IONIS-FXIRx - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Projects 43
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Featured News & Press Releases 44
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 44
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 44
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 45
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 46
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 46
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma 47
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery 48
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 48
Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders 50
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Bayer AG, H2 2016 24
Pipeline by Bristol-Myers Squibb Company, H2 2016 25
Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 26
Pipeline by LegoChem Biosciences, Inc, H2 2016 27
Dormant Projects, H2 2016 43

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22
  • Global Nanofiber Materials Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 125
    Nanofibers are fibers with diameters in the nanometer range. Nanofibers can be generated from different polymers and hence have different physical properties and application potentials. The traditional implant materials have short functional life, with failures arising from implant loosening, inflammation, infection, and wear debris. This resulted in the need for the development of new cytocompatible bone substitutes with substantially enhanced functional life to regenerate bone tissues. ......
  • Global Nucleic Acid Isolation and Purification Market Size, Status and Forecast 2019-2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 108
    Nucleic acid isolation and purification is a procedure of molecular biology techniques such as cloning, sequencing, polymerase chain reaction and others. These techniques have various applications in the field of genetic engineering, life science research, forensics and molecular diagnostics. Nucleic acid isolation and purification has provided information to forensic scientists based on downstream analysis and power to individualize biological evidence to match the criminal. Biological e......
  • Global Mycoplasma Testing Market Insights, Forecast to 2025
    Published: 17-Jan-2019        Price: US 3900 Onwards        Pages: 116
    The major factors driving this market are the increasing growth of government support for pharmaceutical and biotechnology industries, rising R&D activities in life sciences research, and rising cell culture contamination. The Asia region is estimated to grow at the fastest rate which can be attributed to the increasing government investments in pharmaceutical R&D and the increasing trend of pharmaceutical outsourcing. The global Mycoplasma Testing market is valued at xx million US......
  • Global Microfluidics Market Insights, Forecast to 2025
    Published: 16-Jan-2019        Price: US 4900 Onwards        Pages: 121
    Quick returns on investment coupled with the fast results and improved portability of the medical equipment embedded with microfluidics technology are the factors expected to drive the market during the forecast period. Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The global Microfluidics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The obj......
  • Global Mice Model Market Insights, Forecast to 2025
    Published: 16-Jan-2019        Price: US 4900 Onwards        Pages: 111
    Mice models are indispensable in research activities dealing with human disease processes due to striking similarities between the anatomy, physiology, and genetics of humans and mice. The major factor driving the growth of the market is the growing innovations and advances in mice models providing increased options to researchers to conduct research activities in particular diseases. The global Mice Model market is valued at xx million US$ in 2018 and will reach xx million US$ by ......
  • Global Label-Free Detection Market Size, Status and Forecast 2019-2025
    Published: 16-Jan-2019        Price: US 3900 Onwards        Pages: 91
    Innovations in label-free detection technologies, increasing drug discovery programs through research partnerships between pharmaceutical companies and academic institutes, and growth in the global pharmaceutical and biotechnology industries are expected to support market growth. Bio-layer Interferometry to register the highest CAGR during the forecast period. In 2018, the global Label-Free Detection market size was xx million US$ and it is expected to reach xx million US$ by the e......
  • VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmenta......
  • Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indica......
  • Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Voltage-Dependent Calcium Channel Blockers development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administra......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs